Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EnBrace HR for PMS and MRMD
NCT04123483Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial, sponsored by Massachusetts General Hospital. Primary endpoint: Rate of Treatment Response to EnBrace Therapy Measured Using The Daily Record of Severity of Problems at 8 weeks. Planned start Nov 2019; status: withdrawn.
Beyond the preview
Go deeper on NCT04123483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123483.